MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Exact Sciences Corporation Net Debt 2011-2026 | EXAS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Exact Sciences Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -560 M | -526 M | -207 M | -283 M | -137 M | 651 M | 528 M | -73 M | -44.1 M | -36.1 M | 167 M | 109 M | 82.4 M | 22.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 651 M | -560 M | -21.8 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
-6.88 M | $ 22.96 | -0.56 % | $ 99.4 M |  Israel |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Danaher Corporation
DHR
|
13.6 B | $ 237.64 | 1.12 % | $ 174 B | USA |
 |
DarioHealth Corp.
DRIO
|
-12.1 M | $ 12.15 | -5.81 % | $ 345 M | Israel |
 |
Burning Rock Biotech Limited
BNR
|
-76 M | $ 23.25 | -0.66 % | $ 250 M |  China |
 |
DexCom
DXCM
|
-487 M | $ 66.95 | -2.16 % | $ 25.8 B | USA |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-2.64 M | $ 1.59 | -0.94 % | $ 2.02 M | USA |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
-11.9 M | $ 6.12 | - | $ 180 M | USA |
 |
IQVIA Holdings
IQV
|
11.2 B | $ 243.33 | 0.06 % | $ 44.1 B | USA |
 |
Castle Biosciences
CSTL
|
-108 M | $ 39.59 | -0.76 % | $ 1.1 B | USA |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | China |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
Natera
NTRA
|
-177 M | $ 234.65 | -2.05 % | $ 23.1 B | USA |
 |
CareDx, Inc
CDNA
|
-48 M | $ 17.02 | -1.16 % | $ 915 M | USA |
 |
Celcuity
CELC
|
82.8 M | $ 107.43 | 2.63 % | $ 4.24 B | USA |
 |
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Pacific Biosciences of California
PACB
|
-139 M | $ 1.95 | -4.66 % | $ 495 M | USA |
 |
Anixa Biosciences
ANIX
|
-1.04 M | $ 3.41 | -0.29 % | $ 109 K | USA |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 27.84 | -0.2 % | $ 842 M | USA |
 |
QIAGEN N.V.
QGEN
|
1.31 B | $ 48.32 | -0.27 % | $ 10.8 B |  Niderland |
 |
RadNet
RDNT
|
308 M | $ 77.42 | -1.22 % | $ 5.65 B | USA |
 |
Guardant Health
GH
|
646 M | $ 110.18 | 1.32 % | $ 13.5 B | USA |
 |
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-494 M | $ 141.01 | -3.31 % | $ 22.4 B | USA |
 |
Charles River Laboratories International
CRL
|
2.1 B | $ 220.64 | 2.38 % | $ 11.3 B | USA |
 |
Thermo Fisher Scientific
TMO
|
27.3 B | $ 620.69 | 2.34 % | $ 237 B | USA |
 |
Trinity Biotech plc
TRIB
|
55.4 M | $ 0.73 | -1.13 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
-107 M | $ 35.58 | 2.42 % | $ 2.13 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.24 B | $ 175.1 | -1.49 % | $ 19.4 B | USA |
|
Biodesix
BDSX
|
14.5 M | $ 5.46 | -2.15 % | $ 708 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4 B | $ 252.61 | -0.81 % | $ 21.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 183.13 | -2.7 % | $ 15.1 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
183 M | $ 715.47 | 0.43 % | $ 59 B | USA |
 |
Lantheus Holdings
LNTH
|
-346 M | $ 67.98 | 0.19 % | $ 4.7 B | USA |
 |
Agilent Technologies
A
|
1.24 B | $ 148.92 | 2.17 % | $ 45.3 B | USA |
 |
Biomerica
BMRA
|
-1.94 M | $ 2.75 | -4.84 % | $ 6.32 M | USA |
 |
Bioventus
BVS
|
334 M | $ 8.02 | 0.25 % | $ 502 M | USA |